Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Apollomics’ partner, Avistone Biotechnology, received approval from Chinese National Medical Products Administration (NMPA) to commercialize vebreltinib (APL-101) in China Compelling clinical data serving as basis of this approval supports continued development of vebreltinib for the rest of world FOSTER CITY, CALIF. – November 16, 2023 – Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company […]